A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth

Pancreatic cancer is one of the most lethal human diseases, with an all-stage 5-year survival rate below 5%. To date, no effective and specific therapy is available for this disease. Mutations in KRAS are frequently reported in pancreatic and many other cancers; thus, KRAS is an attractive therapeut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Pan, Ting, Zhang, Yiwen, Zhou, Nan, He, Xin, Chen, Cancan, Liang, Liting, Duan, Xiaobing, Lin, Yingtong, Wu, Kang, Zhang, Hui
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190097/
https://ncbi.nlm.nih.gov/pubmed/27322423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados